Altimmune, Inc. to Present Pemvidutide Data at the American Diabetes Association's 85th Scientific Sessions

Altimmune (ALT) will present data on pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for MASH, obesity, AUD, and ALD, at the ADA's 85th Scientific Sessions in June 2025. The presentations will cover pemvidutide's effects on cardioinflammatory lipids, cardiovascular safety, central adiposity correlations, and cholesterol transport enhancements. Pemvidutide has Fast Track designation from the FDA for MASH, with Phase 2b MASH trial results expected in Q2 2025 and ongoing trials for AUD and ALD.

Analysis

Altimmune is strategically advancing its lead candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, with significant upcoming data disclosures at the American Diabetes Association's 85th Scientific Sessions in June 2025. These presentations will focus on pemvidutide's effects on cardioinflammatory lipids, cardiovascular safety, central adiposity correlations, and cholesterol transport enhancements, providing further insight into its broad metabolic benefits. A key inflection point for the company will be the anticipated top-line results from its IMPACT Phase 2b MASH trial in Q2 2025, particularly as pemvidutide holds FDA Fast Track designation for this indication and has previously demonstrated compelling clinical outcomes, including significant weight loss, lean mass preservation, and improvements in triglycerides, LDL cholesterol, and liver fat. While the company is actively developing pemvidutide across multiple indications such as obesity, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD), the current absence of recent data from the ongoing MASH trial and undefined timelines for potential market introduction contribute to investor uncertainty. Insider activity indicates a modest positive signal, with the Chief Financial Officer purchasing 10,000 shares in the past six months. Institutional ownership presents a mixed picture: while 85 institutions added to their positions in the most recent quarter, 96 reduced their holdings. Notably, Marshall Wace, LLP and Millennium Management LLC significantly increased their stakes, whereas Ameriprise Financial Inc. substantially reduced its position, and both Capital Fund Management S.A. (in Q4 2024) and Citadel Advisors LLC fully exited their holdings in Q1 2025.

Key Decisions for Investors

• Investors should closely monitor the forthcoming data presentations at the ADA Scientific Sessions in June 2025 and, more critically, the top-line results from the Phase 2b MASH trial expected in Q2 2025, as these events represent significant near-term catalysts for Altimmune.
• Given Altimmune's status as a late clinical-stage biopharmaceutical company, any investment carries a high-risk, high-reward profile; the potential of pemvidutide must be weighed against the inherent uncertainties in clinical trial outcomes, regulatory approval pathways, and ultimate commercialization timelines, especially considering the mixed institutional sentiment.
• The recent insider purchase by the CFO provides a degree of management confidence, but this should be contextualized within the broader institutional repositioning and the binary nature of biopharmaceutical drug development, warranting a cautious approach pending further clinical validation.